Regenx Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The Company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The Company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, Regenxoffers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers.
Type
Public
HQ
Rockville, US
Founded
2009
Size (employees)
107 (est)+13%
Regenxbio was founded in 2009 and is headquartered in Rockville, US
Report incorrect company information

Key People/Management at Regenxbio

Ken Mills

Ken Mills

President and Chief Executive Officer
Vit Vasista

Vit Vasista

CFO
Stephen Yoo

Stephen Yoo

Chief Medical Officer
Olivier Danos

Olivier Danos

Chief Scientific Officer
Curran Simpson

Curran Simpson

Senior Vice President, Technical Operations
Kimberly Sloan

Kimberly Sloan

Senior Vice President, Human Resources
Show more

Regenxbio Office Locations

Regenxbio has an office in Rockville
Rockville, US (HQ)
100 9712 Medical Center Dr
Show all (1)
Report incorrect company information

Regenxbio Financials and Metrics

Regenxbio Financials

Regenxbio's revenue was reported to be $10.39 m in FY, 2017
USD

Revenue (Q1, 2018)

132.4 m

Net income (Q1, 2018)

104.2 m

EBIT (Q1, 2018)

102 m

Market capitalization (14-Jun-2018)

1.8 b

Closing share price (14-Jun-2018)

56

Cash (31-Mar-2018)

71.9 m
Regenxbio's current market capitalization is $1.8 b.
Annual
USDFY, 2017

Revenue

10.4 m

General and administrative expense

27.2 m

R&D expense

57.2 m

Operating expense total

86.3 m
Quarterly
USDQ1, 2018

Revenue

132.4 m

General and administrative expense

8.4 m

R&D expense

19.6 m

Operating expense total

30.4 m
Annual
USDFY, 2017

Cash

46.7 m

Accounts Receivable

473 k

Current Assets

168 m

PP&E

14 m
Quarterly
USDQ1, 2018

Cash

71.9 m

Accounts Receivable

26 m

Current Assets

262.7 m

PP&E

14.8 m
Annual
USDFY, 2017

Net Income

(73.2 m)

Depreciation and Amortization

2.7 m

Accounts Payable

2.6 m

Cash From Operating Activities

(58 m)
Quarterly
USDQ1, 2018

Net Income

104.2 m

Depreciation and Amortization

834 k

Accounts Payable

477 k

Cash From Operating Activities

58.1 m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Regenxbio Online and Social Media Presence

Embed Graph
Report incorrect company information

Regenxbio News and Updates

Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR

This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…

Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information